levofloxacin has been researched along with oseltamivir in 5 studies
| Studies (levofloxacin) | Trials (levofloxacin) | Recent Studies (post-2010) (levofloxacin) | Studies (oseltamivir) | Trials (oseltamivir) | Recent Studies (post-2010) (oseltamivir) |
|---|---|---|---|---|---|
| 4,346 | 581 | 2,209 | 3,368 | 186 | 2,014 |
| Protein | Taxonomy | levofloxacin (IC50) | oseltamivir (IC50) |
|---|---|---|---|
| Neuraminidase | Influenza A virus (A/Turkey/651242/2006(H5N1)) | 0.1104 | |
| Neuraminidase | Influenza A virus (A/Wilson-Smith/1933(H1N1)) | 0.2616 | |
| Neuraminidase | Influenza A virus (A/duck/Laos/25/2006(H5N1)) | 2.0317 | |
| Neuraminidase | Influenza A virus (A/Puerto Rico/8/1934(H1N1)) | 1.1344 | |
| Neuraminidase | Influenza A virus (A/USSR/90/1977(H1N1)) | 0.002 | |
| Neuraminidase | Influenza B virus (B/Lee/1940) | 0.005 | |
| Acyl-CoA desaturase 1 | Mus musculus (house mouse) | 0.008 | |
| Neuraminidase | Influenza A virus (A/chicken/Yogjakarta/BBVet-IX/2004(H5N1)) | 0.0043 | |
| Neuraminidase | Influenza A virus (A/Thailand/1(KAN-1)/2004(H5N1)) | 0.0003 | |
| Neuraminidase | Influenza A virus (A/Singapore/1/1957(H2N2)) | 0.003 | |
| Neuraminidase | Influenza A virus (A/Aichi/2/1968(H3N2)) | 0.0016 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Aytemir, MD; Ozçelik, B | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Azadi, H; Darabi, E; Fathi, S; Ghanei, M; Ghazale, AH; Ghazvini, A; Izadi, M; Jafari, R; Movaseghi, F; Mozafari, A; Panahi, Y; Parsaei, MR; Ranjkesh, MH; Rezapour, M; Saadat, SH; Salesi, M; Vahedi, E; Zand, N | 1 |
| Akbulut Koyuncu, İM; Kızıltunç, E; Uğurlu Ilgın, B | 1 |
1 review(s) available for levofloxacin and oseltamivir
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
4 other study(ies) available for levofloxacin and oseltamivir
| Article | Year |
|---|---|
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
A study of cytotoxicity of novel chlorokojic acid derivatives with their antimicrobial and antiviral activities.
Topics: Animals; Anti-Infective Agents; Antiviral Agents; Bacteria; Cell Line; Chlorocebus aethiops; Drug Evaluation, Preclinical; Fungi; Herpesvirus 1, Human; Mannich Bases; Microbial Sensitivity Tests; Parainfluenza Virus 3, Human; Pyrones; Spectrum Analysis; Vero Cells | 2010 |
The clinical value of two combination regimens in the Management of Patients Suffering from Covid-19 pneumonia: a single centered, retrospective, observational study.
Topics: Adult; Aged; Azithromycin; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Drug Therapy, Combination; Female; Hospitalization; Humans; Hydroxychloroquine; Iran; Length of Stay; Levofloxacin; Lopinavir; Male; Meropenem; Middle Aged; Naproxen; Oseltamivir; Pneumonia, Viral; Prednisolone; Retrospective Studies; Ritonavir; Treatment Outcome; Vancomycin | 2020 |
Effect of triple antimicrobial therapy on electrocardiography parameters in patients with mild-to-moderate coronavirus disease 2019.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combination; Electrocardiography; Female; Humans; Hydroxychloroquine; Levofloxacin; Long QT Syndrome; Male; Middle Aged; Oseltamivir; Retrospective Studies; SARS-CoV-2; Severity of Illness Index; Treatment Outcome; Young Adult | 2021 |